Aiforia Technologies (AIFORIA) Q4 2025 earnings summary

Executive summary

• Clinical sector revenue grew 68% in FY 2025, driven by portfolio expansion, commercial execution, and flagship customer wins.

• Group revenue increased 24% year-over-year to EUR 3,535 thousand.

• Achieved IVDR certification for five new clinical AI solutions, expanding the CE-IVD marked product portfolio to eleven.

• Strategic partnerships, including Siemens Healthineers and Orion, supported growth and expansion.

• Actions taken to improve cost structure and efficiency, with secured funding and share issues raising EUR 12.2 million.

Financial highlights

• Full-year revenue increased by 24% to EUR 3,535 thousand compared to 2024.

• Clinical sector revenue grew 68% year-over-year, outpacing overall company growth.

• EBITDA improved to EUR -6,045 thousand from EUR -8,220 thousand year-over-year.

• EBIT improved to EUR -11,183 thousand from EUR -12,195 thousand.

• Cash and cash equivalents at year-end were EUR 9,529 thousand.

Outlook and guidance

• No formal short-term financial forecast; medium-term targets include financial independence by 2027 and covering 80% of pathologist workflow by 2030.

• Aim to reach 50 key clinical accounts and leverage technology beyond diagnostic support by 2030.

• Flexibility maintained regarding profitability versus market capture, with potential for additional funding rounds if needed.